# Liver Diseases and Immunity

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/liver-diseases-and-immunity/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the diagnosis, management, epidemiology, and genetic factors of autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis. It also covers topics such as liver transplantation, immunosuppressive therapy, and the pathogenesis of these liver diseases. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11834 |
| Works | 369 |

## Topic papers all

Showing 15 of 369.

- [Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/vedolizumab-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus](https://scholariq.org/papers/development-of-autoantibodies-before-the-clinical-onset-of-systemic-lupus/)
- [Model for end-stage liver disease (MELD) and allocation of donor livers](https://scholariq.org/papers/model-for-end-stage-liver-disease-meld-and-allocation-of-donor-livers/)
- [Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease](https://scholariq.org/papers/sampling-variability-of-liver-biopsy-in-nonalcoholic-fatty-liver-disease/)
- [Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis](https://scholariq.org/papers/global-perspectives-on-nonalcoholic-fatty-liver-disease-and-nonalcoholic/)
- [A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis](https://scholariq.org/papers/a-phase-3-randomized-controlled-trial-of-resmetirom-in-nash-with-liver-fibrosis/)
- [A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus](https://scholariq.org/papers/a-phase-iii-randomized-placebo-controlled-study-of-belimumab-a-monoclonal/)
- [American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis](https://scholariq.org/papers/american-college-of-rheumatology-guidelines-for-screening-treatment-and/)
- [Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study](https://scholariq.org/papers/efficacy-and-safety-of-rituximab-in-patients-with-active-proliferative-lupus/)
- [Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial](https://scholariq.org/papers/efficacy-and-safety-of-rituximab-in-moderately-to-severely-active-systemic-lupus/)
- [ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents](https://scholariq.org/papers/espghan-revised-porto-criteria-for-the-diagnosis-of-inflammatory-bowel-disease/)
- [Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis](https://scholariq.org/papers/severity-of-inflammation-is-a-risk-factor-for-colorectal-neoplasia-in-ulcerative/)
- [Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial](https://scholariq.org/papers/obeticholic-acid-for-the-treatment-of-non-alcoholic-steatohepatitis-interim/)
- [Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis](https://scholariq.org/papers/mycophenolate-mofetil-or-intravenous-cyclophosphamide-for-lupus-nephritis/)
- [Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis](https://scholariq.org/papers/mycophenolate-mofetil-versus-cyclophosphamide-for-induction-treatment-of-lupus/)

## Topic primary papers

Showing 15 of 61.

- [A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis](https://scholariq.org/papers/a-placebo-controlled-trial-of-obeticholic-acid-in-primary-biliary-cholangitis/)
- [Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases](https://scholariq.org/papers/diagnosis-and-management-of-autoimmune-hepatitis-in-adults-and-children-2019/)
- [Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis](https://scholariq.org/papers/population-based-epidemiology-malignancy-risk-and-outcome-of-primary-sclerosing/)
- [Primary sclerosing cholangitis](https://scholariq.org/papers/primary-sclerosing-cholangitis/)
- [Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis](https://scholariq.org/papers/patient-age-sex-and-inflammatory-bowel-disease-phenotype-associate-with-course/)
- [Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy](https://scholariq.org/papers/gut-microbial-profile-is-altered-in-primary-biliary-cholangitis-and-partially/)
- [Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD](https://scholariq.org/papers/primary-sclerosing-cholangitis-is-characterised-by-intestinal-dysbiosis/)
- [Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis](https://scholariq.org/papers/genome-wide-meta-analyses-identify-three-loci-associated-with-primary-biliary/)
- [International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways](https://scholariq.org/papers/international-genome-wide-meta-analysis-identifies-new-primary-biliary-cirrhosis/)
- [The Natural History of Small-Duct Primary Sclerosing Cholangitis](https://scholariq.org/papers/the-natural-history-of-small-duct-primary-sclerosing-cholangitis/)
- [Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis](https://scholariq.org/papers/comparison-of-the-clinical-features-and-clinical-course-of-antimitochondrial/)
- [Human bile contains MicroRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis](https://scholariq.org/papers/human-bile-contains-microrna-laden-extracellular-vesicles-that-can-be-used-for/)
- [Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis](https://scholariq.org/papers/budesonide-combined-with-udca-to-improve-liver-histology-in-primary-biliary/)
- [Metronidazole and Ursodeoxycholic Acid for Primary Sclerosing Cholangitis: A Randomized Placebo–Controlled Trial](https://scholariq.org/papers/metronidazole-and-ursodeoxycholic-acid-for-primary-sclerosing-cholangitis-a/)
- [Gastrointestinal and liver disease](https://scholariq.org/papers/gastrointestinal-and-liver-disease/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.